Medical Research & News

Clinical Trials...Developing Innovative Drug Candidates to Improve the Lives Of Cancer Patients

Two clinical assets of Trillium Therapeutics Inc., TTI-621 and TTI-622, are designed to activate the patient’s innate and adaptive immune response. TTI-621 is an investigational agent being developed by Trillium for the treatment of cutaneous T-cell lymphoma and other cancer types.

Resiquimod Study for Treating Cutaneous T-cell Lymphoma

Early studies show Resiquimod gel as a promising treatment for early stage cutaneous lymphoma. Learn more about this investigator-initiated study.

FDA Approves Mogamulizumab for CTCL

The FDA has approved mogamulizumab-kpkc (Poteligeo) for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy.

Industry Spotlight: Adaptive Biotechnologies

Susan Thornton, CEO, interviewed Adaptive Biotechnologies, creators of an innovative diagnostic tool that can be used in cutaneous lymphoma.

Research in Cutaneous Lymphoma: A Broad View

Since the development of the “scientific method,” people have been engaged in research in efforts to answer questions, solve problems, and add to our overall knowledge. Nowhere is this more evident than in the medical field, and in the study of cutaneous lymphoma.

FLASH Study: Clinical Trial Update

Dr. Ellen Kim shares information about the role of clinical trials and specifically the FLASH [Fluorescent Light Activated Synthetic Hypericin] Study.

Protein Can Help Identify Which Rashes Are Early Mycosis Fungoides

Chronic rash in a sun-protected area that doesn’t respond to topical treatment likely needs to be evaluated for mycosis fungoides, the most common variant of cutaneous T-cell lymphoma. Now, a new VA study reports that a protein expression can help make the diagnosis.

Skin-Directed Tactics Optimal for Early Cutaneous Lymphoma

For patients with early-stage cutaneous lymphoma, skin-directed treatments, such as topical steroids and phototherapy, can slow or halt progression, but patients are also being treated with systemic therapies, according to the first-of-its kind research on this rare malignancy.


Advances are being made in improving diagnostic tools. Dr. Christiane Quelfeld presents what has become available and what the future holds.


New breakthroughs in research offer hope of better treatments and may offer insight into the causes of cutaneous lymphoma.

Modernizing Immunotherapy for Cutaneous T-cell Lymphoma

For decades, immunotherapy has been a cornerstone of systemic therapy for cutaneous T cell lymphoma (CTCL). It is therefore not surprising that modern immune-therapies, which target anti-tumor immunity in more sophisticated ways, have the potential to greatly improve our treatments for CTCL. 

Epigenetics & Biology of Cutaneous T-cell Lymphomas

These are exciting times in cutaneous T-cell lymphoma (CTCL) research. The hard work of laboratory and clinical investigators worldwide is starting to bear fruit, and a number of basic discoveries in the genetic and epigenetic foundations of CTCL are now being translated into novel therapies, with great impact for patients.

Medical Meeting Highlights: 3rd World Congress, T-Cell Lymphoma Forum and USCLC Annual Workshop

In a world that has 7,000 known rare diseases, with only 5% having any treatment available, the future of discovery and new treatment development in cutaneous lymphoma is promising. There is much hope for a brighter future for everyone living with this condition.

Industry Spotlight: Soligenix

Soligenix, Inc. recently to talk about their clinical trial for treating early stage cutaneous lymphoma. The treatment process uses a new topical photosensitizing agent (synthetic hypericin) and fluorescent light.